SCHEMBL3638607

SCHEMBL3638607

O=C(NCCc1cccc(Cl)c1)c1cc(-c2ccc3[nH]ncc3c2)on1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.64
ROCK2 O75116 3/20 0.59
GSK3B P49841 3/20 0.59
PIM1 P11309 2/20 0.59
FAAH O00519 3/20 0.53
TP53 P04637 2/20 0.52
HIF1A Q16665 1/20 0.52
THRB P10828 1/20 0.50
ALDH1A1 P00352 2/20 0.49
MAPK1 P28482 2/20 0.49
LMNA P02545 1/20 0.49
HPGD P15428 1/20 0.49
HSD17B10 Q99714 1/20 0.49
DYRK1A Q13627 3/20 0.49
AURKA O14965 2/20 0.49
DAPK3 O43293 2/20 0.49
JAK2 O60674 2/20 0.49
FGFR1 P11362 2/20 0.49
PRKACA P17612 2/20 0.49
KDR P35968 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3668000 0.91 ROCK2 (0.61) MAPTROCK2GSK3BPIM1TP53
SCHEMBL3634175 0.90 ROCK2 (0.62) MAPTROCK2GSK3BPIM1FAAH
SCHEMBL3670768 0.89 FAAH (0.67) MAPTROCK2GSK3BPIM1FAAH
SCHEMBL3668414 0.86 ROCK2 (0.60) MAPTROCK2GSK3BPIM1FAAH
SCHEMBL3636595 0.85 ROCK2 (0.61) MAPTROCK2GSK3BPIM1FAAH
SCHEMBL3666993 0.85 ROCK2 (0.64) MAPTROCK2GSK3BPIM1FAAH
SCHEMBL3669367 0.82 ROCK2 (0.65) MAPTROCK2GSK3BPIM1TP53
SCHEMBL3670364 0.81 ROCK2 (0.67) MAPTROCK2GSK3BPIM1FAAH
SCHEMBL3667340 0.81 ROCK2 (0.70) ROCK2GSK3BPIM1FAAHTP53
SCHEMBL3667526 0.81 ROCK2 (0.58) MAPTROCK2GSK3BPIM1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 MAPT 1170/4885ROCK2 48/4885GSK3B 1/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 MAPT 1170/4885ROCK2 48/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.